DLH Reports Fiscal 2021 Second Quarter Results
DLH Holdings Corp. (NASDAQ: DLHC) reported a revenue increase to $61.5 million for Q2 FY2021, up from $54.8 million in Q2 FY2020, largely due to the acquisition of IBA. Operating margins expanded to 7.5%, with earnings of $2.6 million ($0.19 per share), compared to $2.1 million ($0.16 per share) the previous year. A significant contract award from the VA for $202 million further enhances revenue visibility. The company’s backlog stood at $608.7 million as of March 31, 2021, excluding the new contract.
- Q2 FY2021 revenue increased by 12% year-over-year.
- Operating margins improved to 7.5%, up from 7.0% in the previous year.
- Net income rose to $2.6 million, $0.19 per diluted share, compared to $2.1 million, $0.16 per share last year.
- Announced a $202 million contract with the VA, enhancing revenue visibility.
- Travel-related program revenue decreased due to COVID-19 impacts.
- Interest expense increased to $1.0 million due to higher debt levels.
Revenue Milestone of
ATLANTA, May 05, 2021 (GLOBE NEWSWIRE) -- DLH Holdings Corp. (NASDAQ: DLHC) (“DLH” or the “Company”), a leading provider of innovative healthcare services and solutions to federal agencies, today announced financial results for its fiscal second quarter ended March 31, 2021.
Highlights
- Second quarter revenue increased to
$61.5 million in fiscal 2021 from$54.8 million in fiscal 2020, reflecting the acquisition of Irving Burton Associates (“IBA”) - Operating margins rose to
7.5% in the current year second quarter from7.0% in the prior-year period - Earnings were
$2.6 million , or$0.19 per diluted share, for the fiscal 2021 second quarter versus$2.1 million , or$0.16 per diluted share, for the second quarter of fiscal 2020 - After the end of the quarter, in April 2021, the Company announced it had won the Consolidated Mail Outpatient Pharmacy ("CMOP") logistics recompete with U.S. Department of Veterans Affairs ("VA"), worth approximately
$202 million over five years - Contract backlog was
$608.7 million as of March 31, 2021, excluding the subsequent CMOP logistics award of approximately$202 million .
Management Discussion
“We continued to see positive trends this quarter impacting all aspects of our performance, supporting our confidence for the year ahead,” said DLH President and Chief Executive Officer Zach Parker. “Revenue rose
"In April, we announced that the VA had awarded us a follow-on contract to provide medical logistics for its CMOP program, which we’ve now managed for over two decades. The VA’s confidence in our ability to continue providing this invaluable service – made even more important by the pandemic – speaks volumes to the capabilities of our staff and demonstrates our commitment to this agency. We are honored by the award of this contract, which includes a base period of one year and four one-year options, providing enhanced revenue visibility and stability."
Results for the Three Months Ended March 31, 2021
Revenue for the second quarter of fiscal 2021 was
Income from operations was
For the three months ended March 31, 2021 and 2020, respectively, DLH recorded a
On a non-GAAP basis, EBITDA for the three months ended March 31, 2021 was approximately
Key Financial Indicators
Fiscal year to date, DLH has generated
As of March 31, 2021, the Company had cash and cash equivalents of
At March 31, 2021, total backlog was approximately
Conference Call and Webcast Details
DLH management will discuss second quarter results and provide a general business update, including current competitive conditions and strategies, during a conference call beginning at 11:00 AM Eastern Time Thursday, May 6, 2021. Interested parties may listen to the conference call by dialing 888-347-5290 or 412-317-5256. Presentation materials will also be posted on the Investor Relations section of the DLH website prior to the commencement of the conference call.
A digital recording of the conference call will be available for replay two hours after the completion of the call and can be accessed on the DLH Investor Relations website or by dialing 877-344-7529 and entering the conference ID 10155504.
About DLH
DLH delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,200 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit www.DLHcorp.com.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or DLH`s future financial performance. Any statements that refer to expectations, projections or other characterizations of future events or circumstances or that are not statements of historical fact (including without limitation statements to the effect that the Company or its management “believes”, “expects”, “anticipates”, “plans”, “intends” and similar expressions) should be considered forward looking statements that involve risks and uncertainties which could cause actual events or DLH’s actual results to differ materially from those indicated by the forward-looking statements. Forward-looking statements in this release include, among others, statements regarding estimates of future revenues, operating income, earnings and cash flow. These statements reflect our belief and assumptions as to future events that may not prove to be accurate. Our actual results may differ materially from such forward-looking statements made in this release due to a variety of factors, including: the outbreak of the novel coronavirus (“COVID-19”), including the measures to reduce its spread, and its impact on the economy and demand for our services, are uncertain, cannot be predicted, and may precipitate or exacerbate other risks and uncertainties; the risk that we will not realize the anticipated benefits of our recent or any future acquisition; the challenges of managing larger and more widespread operations resulting from our recent acquisition; contract awards in connection with re-competes for present business and/or competition for new business; compliance with new bank financial and other covenants; changes in client budgetary priorities; government contract procurement (such as bid and award protests, small business set asides, loss of work due to organizational conflicts of interest, etc.) and termination risks; the ability to successfully integrate the operations our recent acquisition and of any future acquisitions; and other risks described in our SEC filings. For a discussion of such risks and uncertainties which could cause actual results to differ from those contained in the forward-looking statements, see “Risk Factors” in the Company’s periodic reports filed with the SEC, including our Annual Report on Form 10-K for the fiscal year ended September 30, 2020, as well as subsequent reports filed thereafter. The forward-looking statements contained herein are not historical facts, but rather are based on current expectations, estimates, assumptions and projections about our industry and business. Such forward-looking statements are made as of the date hereof and may become outdated over time. The Company does not assume any responsibility for updating forward-looking statements, except as may be required by law.
CONTACTS:
INVESTOR RELATIONS |
Contact: Chris Witty |
Phone: 646-438-9385 |
Email: cwitty@darrowir.com |
TABLES TO FOLLOW
DLH HOLDINGS CORP.
CONSOLIDATED STATEMENTS OF INCOME
(Amounts in thousands except per share amounts)
(unaudited) | ||||||||||||||||
Three Months Ended | Six Months Ended | |||||||||||||||
March 31, | March 31, | |||||||||||||||
2021 | 2020 | 2021 | 2020 | |||||||||||||
Revenue | $ | 61,506 | $ | 54,798 | $ | 119,358 | $ | 107,036 | ||||||||
Cost of Operations: | ||||||||||||||||
Contract costs | 48,722 | 42,941 | 94,727 | 84,281 | ||||||||||||
General and administrative costs | 6,135 | 6,260 | 12,285 | 12,174 | ||||||||||||
Depreciation and amortization | 2,029 | 1,760 | 4,091 | 3,619 | ||||||||||||
Total operating costs | 56,886 | 50,961 | 111,103 | 100,074 | ||||||||||||
Income from operations | 4,620 | 3,837 | 8,255 | 6,962 | ||||||||||||
Interest expense, net | 1,004 | 906 | 2,084 | 1,846 | ||||||||||||
Income before income taxes | 3,616 | 2,931 | 6,171 | 5,116 | ||||||||||||
Income tax expense | 1,049 | 855 | 1,790 | 1,488 | ||||||||||||
Net income | $ | 2,567 | $ | 2,076 | $ | 4,381 | $ | 3,628 | ||||||||
Net income per share - basic | $ | 0.20 | $ | 0.17 | $ | 0.35 | $ | 0.30 | ||||||||
Net income per share - diluted | $ | 0.19 | $ | 0.16 | $ | 0.32 | $ | 0.28 | ||||||||
Weighted average common shares outstanding | ||||||||||||||||
Basic | 12,544 | 12,299 | 12,521 | 12,193 | ||||||||||||
Diluted | 13,570 | 13,003 | 13,568 | 12,886 |
DLH HOLDINGS CORP.
CONSOLIDATED BALANCE SHEETS
(Amounts in thousands except par value of shares)
March 31, 2021 | September 30, 2020 | |||||||
(unaudited) | ||||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 420 | $ | 1,357 | ||||
Accounts receivable | 41,675 | 32,541 | ||||||
Other current assets | 3,469 | 3,499 | ||||||
Total current assets | 45,564 | 37,397 | ||||||
Equipment and improvements, net | 2,593 | 3,339 | ||||||
Operating lease right-of-use assets | 21,055 | 22,427 | ||||||
Deferred taxes, net | — | 37 | ||||||
Goodwill | 65,643 | 67,144 | ||||||
Intangible assets, net | 50,762 | 52,612 | ||||||
Other long-term assets | 539 | 606 | ||||||
Total assets | $ | 186,156 | $ | 183,562 | ||||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||||||
Current liabilities: | ||||||||
Debt obligations - current, net of deferred financing costs | $ | 3,124 | $ | 6,727 | ||||
Operating lease liabilities - current | 2,130 | 2,045 | ||||||
Accrued payroll | 12,012 | 10,611 | ||||||
Accounts payable, accrued expenses, and other current liabilities | 30,824 | 28,578 | ||||||
Total current liabilities | 48,090 | 47,961 | ||||||
Long-term liabilities: | ||||||||
Deferred taxes, net | 1,475 | — | ||||||
Debt obligations - long term, net of deferred financing costs | 57,199 | 60,544 | ||||||
Operating lease liabilities - long-term | 20,499 | 21,620 | ||||||
Total long-term liabilities | 79,173 | 82,164 | ||||||
Total liabilities | 127,263 | 130,125 | ||||||
Shareholders' equity: | ||||||||
Common stock, | 13 | 12 | ||||||
Additional paid-in capital | 86,942 | 85,868 | ||||||
Accumulated deficit | (28,062 | ) | (32,443 | ) | ||||
Total shareholders’ equity | 58,893 | 53,437 | ||||||
Total liabilities and shareholders' equity | $ | 186,156 | $ | 183,562 |
DLH HOLDINGS CORP.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(Amounts in thousands)
Six Months Ended | ||||||||
March 31, | ||||||||
2021 | 2020 | |||||||
(unaudited) | ||||||||
Operating activities | ||||||||
Net income | $ | 4,381 | $ | 3,628 | ||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation and amortization expense | 4,091 | 3,619 | ||||||
Amortization of deferred financing costs | 413 | 374 | ||||||
Stock based compensation expense | 844 | 384 | ||||||
Deferred taxes, net | 1,512 | 1,258 | ||||||
Gain from lease modification | — | (121 | ) | |||||
Changes in operating assets and liabilities | ||||||||
Accounts receivable | (9,134 | ) | (11,722 | ) | ||||
Other current assets | 30 | (1,211 | ) | |||||
Accrued payroll | 1,401 | 1,913 | ||||||
Accounts payable, accrued expenses, and other current liabilities | 2,245 | 2,280 | ||||||
Other long-term assets/liabilities | 336 | 260 | ||||||
Net cash provided by operating activities | 6,119 | 662 | ||||||
Investing activities | ||||||||
Business acquisition adjustment, net of cash acquired | 59 | — | ||||||
Purchase of equipment and improvements | (53 | ) | (141 | ) | ||||
Net cash provided by (used in) investing activities | 6 | (141 | ) | |||||
Financing activities | ||||||||
Borrowing on revolving line of credit, net | — | 2,000 | ||||||
Repayment of senior debt | (7,250 | ) | (3,000 | ) | ||||
Payment of deferred financing costs | (43 | ) | (3 | ) | ||||
Repurchased shares of common stock | — | (211 | ) | |||||
Proceeds from issuance of common stock upon exercise of options | 231 | 27 | ||||||
Net cash used in financing activities | (7,062 | ) | (1,187 | ) | ||||
Net change in cash and cash equivalents | (938 | ) | (666 | ) | ||||
Cash and cash equivalents at beginning of year | 1,357 | 1,790 | ||||||
Cash and cash equivalents at end of year | $ | 420 | $ | 1,124 | ||||
Supplemental disclosures of cash flow information | ||||||||
Cash paid during the period for interest | $ | 1,639 | $ | 1583 | ||||
Cash paid during the period for income taxes | $ | 184 | $ | 409 | ||||
Supplemental disclosures of non-cash activity | ||||||||
Non-cash cancellation of common stock | $ | — | $ | 211 |
Revenue Metrics
Six Months Ended | ||||||
March 31, | March 31, | |||||
2021 | 2020 | |||||
Market Mix: | ||||||
Defense/VA | 59 | % | 47 | % | ||
Human Services and Solutions | 14 | % | 21 | % | ||
Public Health/Life Sciences | 27 | % | 32 | % | ||
Contract Mix: | ||||||
Time and materials | 76 | % | 70 | % | ||
Cost reimbursable | 20 | % | 28 | % | ||
Firm fixed price | 4 | % | 2 | % | ||
Prime vs Sub: | ||||||
Prime | 89 | % | 93 | % | ||
Subcontractor | 11 | % | 7 | % |
Non-GAAP Financial Measures
The Company uses EBITDA and EBITDA as a percent of revenue as supplemental non-GAAP measures of performance. We define EBITDA as net income excluding (i) interest expense, (ii) provision for or benefit from income taxes and (iii) depreciation and amortization. EBITDA as a percent of revenue is EBITDA for the measurement period divided by revenue for the same period.
These non-GAAP measures of performance are used by management to conduct and evaluate its business during its review of operating results for the periods presented. Management and the Company's Board utilize these non-GAAP measures to make decisions about the use of the Company's resources, analyze performance between periods, develop internal projections and measure management performance. We believe that these non-GAAP measures are useful to investors in evaluating the Company's ongoing operating and financial results and understanding how such results compare with the Company's historical performance.
Reconciliation of GAAP net income to EBITDA, a non-GAAP measure:
(amounts in thousands) | Three Months Ended | Six Months Ended | ||||||||||||||||||||||
March 31, | March 31, | |||||||||||||||||||||||
2021 | 2020 | Change | 2021 | 2020 | Change | |||||||||||||||||||
Net income | $ | 2,567 | $ | 2,076 | $ | 491 | $ | 4,381 | $ | 3,628 | $ | 753 | ||||||||||||
(i) Interest expense, net | 1,004 | 906 | 98 | 2,084 | 1,846 | 238 | ||||||||||||||||||
(ii) Provision for taxes | 1,049 | 855 | 194 | 1,790 | 1,488 | 302 | ||||||||||||||||||
(iii) Depreciation and amortization | 2,029 | 1,760 | 269 | 4,091 | 3,619 | 472 | ||||||||||||||||||
EBITDA | $ | 6,649 | $ | 5,597 | $ | 1,052 | $ | 12,346 | $ | 10,581 | $ | 1,765 | ||||||||||||
Net income as a % of revenue | 4.2 | % | 3.7 | % | 0.5 | % | 3.7 | % | 3.4 | % | 0.3 | % | ||||||||||||
EBITDA as a % of revenue | 10.8 | % | 10.2 | % | 0.6 | % | 10.3 | % | 9.9 | % | 0.4 | % | ||||||||||||
Revenue | $ | 61,506 | $ | 54,798 | $ | 6,708 | $ | 119,358 | $ | 107,036 | $ | 12,322 |
FAQ
What were DLHC's revenue results for Q2 FY2021?
How has DLHC's operating margin changed in Q2 FY2021?
What was DLHC's net income for Q2 FY2021?
What significant contract did DLHC win recently?